| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
NYSE: ATHN |
| Security Type |
Common Stock |
| Lead Underwriter |
UBS Warburg |
| Days In Registration |
1072 |
| Date Filed |
31-Oct-2001 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Healthcare |
| Business Description |
Pvd esoteric testing services in the field of neurology; identify, license and commercially develop new esoteric assays and, through the sales force, market them directly to neurologists |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
- |
| CEO |
Robert E. Flaherty |
| Number of Employees |
121 |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
- |
| File Amount |
- |
| File Price Range |
- - - |
| File Mid Price |
- |
|
